High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.

about

High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.

Item

http://www.wikidata.org/entity/Q40158700

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

High dose IVIG successfully re ...... fantile Pompe disease patient.

@en

type

Item

label

High dose IVIG successfully re ...... fantile Pompe disease patient.

@en

prefLabel

High dose IVIG successfully re ...... fantile Pompe disease patient.

@en

P1476

High dose IVIG successfully re ...... fantile Pompe disease patient.

@en

P2093

Amy Rosenberg

http://www.w3.org/2001/XMLSchema#string

Ankit Desai

http://www.w3.org/2001/XMLSchema#string

Crista Walters

http://www.w3.org/2001/XMLSchema#string

Mugdha Rairikar

http://www.w3.org/2001/XMLSchema#string

Priya S Kishnani

http://www.w3.org/2001/XMLSchema#string

Zoheb B Kazi

http://www.w3.org/2001/XMLSchema#string

P2860

Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Pompe disease: from pathophysiology to therapy and back again

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.

P31

scholarly article

P356

10.1016/J.YMGME.2017.05.006

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28648664

http://www.w3.org/2001/XMLSchema#string

P932

5612830

http://www.w3.org/2001/XMLSchema#string